NAPPA appoints Dr. Wu Zhou as Regional Head for Malaysia, Indonesia, and Vietnam
Pharmasolution Asia's founder joins NAPPA to drive strategic synergy between southern China and Southeast Asian life sciences.
NAPPA has appointed Dr. Wu Zhou as Regional Head for Malaysia, Indonesia, and Vietnam. The appointment formalizes NAPPA’s reach into Southeast Asia’s three-country emerging biopharma corridor and strengthens connectivity between the Guangdong–Hong Kong–Macao Greater Bay Area and ASEAN markets.
Background
Dr. Zhou is Founder and Chairman of Pharmasolution Asia and Managing Director of Chengye Capital. Pharmasolution Asia provides end-to-end services for pharma companies entering Southeast Asia — from regulatory registration through market access. Since 2024 his firm has supported the launch of 20+ products in the region.
He previously held leadership roles at Pfizer, Daiichi Sankyo, and GSK. Education: Master’s in Chinese Medicine, Hong Kong Baptist University; EMBA, HKU Business School.
Focus areas
- ACTD registration and NPP frameworks across Malaysia, Indonesia, and Vietnam
- Cross-border R&D and clinical transformation of high-quality assets
- Capital connectivity via LPF/SPC fund structures
- Internationalized review-standard alignment across the region
- Local NAPPA chapter building and member network development